Answers are grounded in this paper and cite their sources.
The crystallization of a pharmaceutical compound, of an active pharmaceutical ingredient, is governed by a set of interdependent requirements. Two of the most prominent parameters are polymorphism and crystal or particle size distribution. The requirements for these parameters are governed by regulatory issues as well as by demands arising from the formulation process and the use of the drug substance. This paper focuses on the optimal choice of the modification of the active pharmaceutical ingredient and on the controlled crystallization of the polymorph chosen. These requirements are checked against the processes used to control particle size.
No takes yet. Share an insight, caveat, or question.
Wolfgang Beckmann (2003) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: